How Biologics and tsDMARDs Can Help Manage Psoriasis?

Speciality: Dermatology


Speaker:

Dr. Sanjiv Kandhari | MD,Sr.Consultant Dermatologist, Dr Kandhari’s Skin & Dental Clinic

Dr. Sumeet Agrawal | MD, DM (Clinical Immunology), Consultant Rheumatologist Artemis Hospital

Dr. Monica Bambroo | MBBS,DVD,FCPS, Consultant Dermatologist HOD(Dermatology) at Artemis Hospital

Description:

A warm welcome to all the medical professionals in this interesting session of use of biologics and tsDMARD in management of psoriasis. In this webinar, the speakers, Dr. Sumeet Agrawal and Dr. Monica Bambroo along with the chairperson Dr. Sanjiv Kandhari have shared the important facts associated with incidence and management of psoriasis.
 
In this webinar, an elaborate discussion on psoriasis is done. The primary subject of discussion in this webinar is immunological responses in psoriasis and the treatment approaches with the use of DMARDs, NSAIDs or other biologics.

Psoriasis is a skin condition, where itchy, scaly patches kind of rashes develop mostly on the knees, elbows, trunk and scalp. It is a common, long-term (chronic) disease with no potential cure. The condition can be painful and can interfere with activities like sleeping and concentrating.

Basically steroid creams or ointments (topical corticosteroids) are used to treat the disease condition. However, in special cases like pregnancy, care needs to be taken in prescribing the medicines. The use of biologics and DMARDs can give better outcomes by slowing the processes in the body that cause joint damage.

Moreover, psoriasis is common dermatosis in children also, the majority of the psoriatic population develop the disease condition during their early phase of life. Hence, ensuring prevention and control during pediatric onset of psoriasis is also considerably important.

 

See More Webinars @ Hidoc Webinars&

See More Webinars @ Hidoc Webinars




Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Why preventive mastectomy isn't offered to everyone at risk

2.

Financial hardship common in patients with cancer

3.

Academics + Pharma = Big Bucks; New CAR-T Warnings; Patients Seek Cancer Tests.

4.

Acalabrutinib + Venetoclax Combo Earns FDA Nod for CLL

5.

Severe obesity associated with reduced prevalence of recommended cancer screenings


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot